Related Experiment Video
Updated: Mar 12, 2026

Vessel-sparing Excision and Primary Anastomosis
Published on: January 7, 2019
Combination therapy only shows short-term superiority over monotherapy on ureteral stent-related symptoms - outcome
Qinyu Liu1, Banghua Liao1, Ruochen Zhang1
1Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
Background:
Controversy remains on the superiority of combination therapy over monotherapy on ureteral stent-related symptoms (SRSs). We tend to explore if there is a necessity of combination therapy.
Methods:
One hundred cases of unilateral upper urinary tract calculi with stent insertion (pre and post flexible ureteroscopy) were randomized into 4 groups, given non-treatment, solifenacin, tamsulosin or combination respectively. Eight times of follow-ups were given after each insertion.
Results:
SRSs released spontaneously within 4 days after insertion (p = 0.017) but then stay with no further improvement. Benefit of solifenacin on flank pain started showing after day4 (p = 0.002), which was comparable to that of tamsulosin and combination (p = 0.914 vs 0.195). Combination therapy showed superiority over both monotherapy before day4, but after then solifenacin and tamsulosin showed similar effectiveness with the combination therapy on both bladder pain (p = 0.229 vs 0.394) and urgency (p = 0.813 vs 0.974). No improvement on hematuria or frequency was observed in each group.
Conclusions:
Combination therapy takes effect faster but shows no supervisory after the first few days compared with monotherapy.
Trial Registration:
The study protocol was registered on Chinese Clinical Trial Register on April 17th, 2013 (registration number: ChiCTR-TRC-13003148 ).
Related Concept Videos
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Urinary Tract Calculi III: Medical Management
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

